MIM
PLX icon

MetLife Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

MetLife Investment Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Buy
45,500
+1,803
+4% +$3.82K ﹤0.01% 2754
2026
Q1 		$94.8K Buy
+43,697
New +$108K ﹤0.01% 2565
2023
Q3 		– Sell
-32,363
Closed -$64.7K – 2958
2023
Q2 		$64.7K Buy
+32,363
New +$77.1K ﹤0.01% 2869

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

MetLife Investment Management's PLX Position: Q2 2026 in Review

MetLife Investment Management increased its Protalix BioTherapeutics (PLX) stake by 4.1% in Q2 2026, buying an estimated $3.82K and bringing the position to 45,500 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

MetLife Investment Management first reported a position in PLX in Q2 2023 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • MetLife Investment Management held 45,500 shares of Protalix BioTherapeutics worth $106K as of Q2 2026.
  • MetLife Investment Management bought 1,803 Protalix BioTherapeutics shares in Q2 2026, an estimated $3.82K.
  • Protalix BioTherapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2754 holding.
  • MetLife Investment Management first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.